Molecular classification of gliomas.

Area of Science:

• Neuro-oncology
• Molecular diagnostics
• Cancer genomics

Background:

• Distinct genetic and epigenetic profiles in gliomas necessitate updated classification systems.
• The 2016 World Health Organization (WHO) classification incorporates molecular markers for an integrated diagnosis.
• Traditional histologic criteria alone are insufficient for accurate glioma diagnosis and treatment planning.

Purpose of the Study:

• To review current diagnostic, prognostic, and predictive molecular biomarkers for gliomas.
• To highlight the role of molecular markers in refining glioma classification and predicting therapy response.
• To discuss the impact of molecular diagnostics on targeted therapy strategies and personalized treatment.

Main Methods:

• Focus on key molecular markers: IDH1/IDH2, ATRX, 1p/19q co-deletion, TERT promoter mutations (adults); BRAF, H3F3A aberrations (pediatric).
• Review of prognostic markers like MGMT promoter methylation.
• Discussion of multiomics data integration for defining glioblastoma subtypes.
• Examination of detection methods including individual marker assays, DNA methylation profiling, and next-generation sequencing.

Main Results:

• Molecular biomarkers are crucial for refined glioma classification, moving beyond histology.
• Specific mutations and alterations (e.g., IDH1/IDH2, ATRX, 1p/19q, TERT, BRAF, H3F3A) are vital for diagnosis and prognosis.
• MGMT promoter methylation is a key predictive marker for therapy response.
• Multiomics data integration defines biologically relevant glioblastoma subtypes.

Conclusions:

• The integrated diagnosis combining histology and molecular data is the new standard for glioma classification.
• Molecular markers significantly improve diagnostic accuracy, prognostic prediction, and therapeutic guidance.
• Advances in molecular diagnostics are paving the way for novel targeted therapies and personalized medicine in glioma treatment.
• Continued research into multiomics and novel diagnostic techniques will further enhance glioma patient care.